List of Excipients in Branded Drug ARAKODA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
60 Degrees Pharmaceuticals INC	ARAKODA	tafenoquine	71475-257	CELLULOSE, MICROCRYSTALLINE	2035-12-02
60 Degrees Pharmaceuticals INC	ARAKODA	tafenoquine	71475-257	FERRIC OXIDE RED	2035-12-02
60 Degrees Pharmaceuticals INC	ARAKODA	tafenoquine	71475-257	HYPROMELLOSE	2035-12-02
60 Degrees Pharmaceuticals INC	ARAKODA	tafenoquine	71475-257	MAGNESIUM STEARATE	2035-12-02
60 Degrees Pharmaceuticals INC	ARAKODA	tafenoquine	71475-257	MANNITOL	2035-12-02
60 Degrees Pharmaceuticals INC	ARAKODA	tafenoquine	71475-257	POLYETHYLENE GLYCOL	2035-12-02
60 Degrees Pharmaceuticals INC	ARAKODA	tafenoquine	71475-257	TITANIUM DIOXIDE	2035-12-02

Arakoda Excipient Strategy and Commercial Opportunities for Tafenoquine

Last updated: August 28, 2026

Arakoda is a 100 mg tafenoquine succinate tablet approved by the FDA for malaria prophylaxis in adults. Its commercial value comes from long-acting weekly dosing, military and government use, and potential travel-medicine demand. The main excipient opportunities are a higher-strength tablet, pediatric or weight-based delivery, improved field stability, and alternative oral formats. The existing product uses a conventional immediate-release tablet platform, leaving room for lifecycle management if the sponsor can improve dose administration without reducing tafenoquine exposure or compromising stability.

What is Arakoda and how is tafenoquine administered?

Arakoda contains tafenoquine, an 8-aminoquinoline antimalarial with activity against liver-stage and blood-stage Plasmodium parasites. The FDA-approved regimen uses multiple 100 mg tablets:

Treatment phase	FDA-approved regimen
Loading dose	200 mg daily for 3 days before travel
Maintenance dose	200 mg once weekly during travel
Terminal dose	200 mg once, 7 days after the last maintenance dose
Tablet strength	100 mg tafenoquine per tablet
Approved population	Adults
Indication	Malaria prophylaxis
FDA approval	2018
NDA	210607

The regimen requires two tablets per administration. Tafenoquine has a long terminal half-life, which supports weekly maintenance dosing but also extends exposure if adverse reactions occur. Arakoda is contraindicated in individuals with glucose-6-phosphate dehydrogenase deficiency or unknown G6PD status, and it is not recommended for people with a history of psychotic disorders. The label also restricts use in pregnancy and lactation under specified circumstances. [1]

The formulation therefore has two commercial priorities: preserve reliable systemic exposure and simplify administration without increasing the risk from prolonged drug exposure.

What excipients are used in Arakoda tablets?

The Arakoda tablet is an immediate-release, film-coated formulation. The inactive ingredients identified in the FDA prescribing information and product labeling include mannitol, copovidone, crospovidone, magnesium stearate and film-coating components supplied through an Opadry-type coating system. [1,2]

Formulation function	Arakoda excipient or excipient class	Commercial role
Diluent and mouthfeel modifier	Mannitol	Provides tablet mass and can support a less chalky oral profile
Binder and granulation aid	Copovidone	Supports mechanical strength and manufacturability
Superdisintegrant	Crospovidone	Promotes tablet breakup after oral administration
Lubricant	Magnesium stearate	Reduces tooling friction and tablet ejection force
Film coating	Opadry-type system, including polymeric coating materials and pigments	Protects the core, improves appearance and handling

The platform is conventional and commercially practical. It does not depend on a lipid carrier, amorphous solid dispersion, controlled-release polymer or specialized absorption enhancer. That reduces manufacturing complexity and may facilitate generic development.

The product’s use of a salt form, tafenoquine succinate, remains important. The salt affects drug loading, crystallinity, powder behavior and tablet content uniformity. Any reformulation must evaluate whether the active pharmaceutical ingredient remains in the same solid form or changes to a different salt, polymorph, hydrate or amorphous state.

Which excipient strategies could improve Arakoda?

Can a 200 mg tablet reduce pill burden?

The clearest opportunity is a 200 mg tablet that allows one tablet per loading, maintenance and terminal dose. Arakoda currently requires two 100 mg tablets per administration. A 200 mg tablet could reduce packaging volume, dispensing complexity and administration errors, particularly for military personnel, travelers and public-health programs.

A 200 mg product would require more than simply doubling tablet weight. Development would need to establish:

• Dose proportionality between 100 mg and 200 mg tablets.
• Comparable dissolution across physiological pH conditions.
• Content uniformity at the larger drug load.
• Mechanical strength during transport and field handling.
• Comparable exposure under fed and fasting conditions.
• Chemical and physical stability during the proposed shelf life.

A 200 mg product could be filed as a new strength under the existing NDA, subject to FDA requirements for pharmaceutical equivalence, bioavailability and manufacturing controls. If the formulation changes materially, the sponsor may need comparative clinical pharmacology data.

Could a dispersible or orally disintegrating formulation expand the market?

A dispersible tablet, orally disintegrating tablet or granule product could address patients who have difficulty swallowing conventional tablets. It could also support administration in military settings and government programs where water access is inconsistent.

The principal technical issue is taste. Tafenoquine is an aminoquinoline and may present bitterness or metallic taste. A dispersible or orally disintegrating product would likely require:

• Taste masking through polymer coating or ion-exchange resins.
• A sweetener and flavor system compatible with long-term stability.
• A low-moisture packaging configuration.
• Rapid dispersion without excessive residue.
• Control of dose uniformity after partial administration.

Mannitol is already compatible with orally disintegrating platforms because it provides cooling mouthfeel and compressibility. Crospovidone could support rapid disintegration, although the excipient level and particle size would require optimization. A commercial product could use coated tafenoquine particles embedded in a mannitol-based matrix.

This opportunity is strongest for pediatric development, patients with dysphagia and field use. It is weaker for ordinary adult travelers who can generally take two conventional tablets.

Is a liquid formulation commercially attractive?

A tafenoquine oral suspension could support weight-based dosing and pediatric use. The opportunity is constrained by the drug’s long half-life and the need to avoid dosing errors. A liquid product would also face stability challenges involving sedimentation, redispersibility, preservative compatibility and container adsorption.

A liquid product would need a robust dosing device, likely an oral syringe rather than a household spoon. The formulation could use a suspending polymer, wetting agent, buffer and preservative, but each additional excipient creates regulatory and supply-chain requirements.

A ready-to-use liquid is less attractive than a powder for reconstitution because malaria prophylaxis may be initiated before travel and used intermittently. A powder for reconstitution could have better shelf stability, but it would add preparation steps and increase the risk of incorrect reconstitution in field environments.

Can excipients improve stability in hot and humid markets?

Tafenoquine products may be distributed in tropical regions and carried in environments with elevated heat and humidity. Excipient and packaging selection can support stability through:

• Low-moisture tablet manufacture.
• Moisture-barrier film coating.
• High-barrier blister packaging.
• Desiccant-equipped bottles.
• Reduced hygroscopicity in the tablet core.
• Tight control of residual solvents and water activity.

The commercial opportunity is strongest in military procurement, humanitarian supply and government stockpiles. A formulation with a longer in-use period after opening could reduce waste in institutional channels.

Packaging is as important as the excipient system. A technically stable tablet can still fail commercial use if tablets are exposed repeatedly to humidity after a bottle is opened. Unit-dose blistering may be preferable for travel and deployment, while bottles may have lower packaging cost for high-volume public-health procurement.

What formulation patents could protect Arakoda lifecycle products?

The original tafenoquine composition-of-matter protection is historical and does not provide a strong current barrier to all product development. The most valuable patent opportunities now would involve formulation-specific claims rather than the active molecule alone.

Potential claim categories include:

Claim category	Potential commercial protection
High-strength tablet	200 mg tablet with specified dissolution, hardness and impurity profile
Taste-masked particles	Coated tafenoquine particles in a dispersible or orally disintegrating dosage form
Pediatric formulation	Weight-based liquid, granule or dispersible formulation
Stability formulation	Excipient combination that limits degradation under heat and humidity
Packaging system	Tablet and moisture-barrier package with defined stability performance
Combination product	Tafenoquine with another antimalarial or travel-health product
Manufacturing process	Granulation, coating or compression process that improves content uniformity

Formulation patent strength would depend on whether the claims contain measurable technical limitations. Broad claims covering only “tafenoquine plus a conventional tablet excipient” would face vulnerability to obviousness and enablement challenges. Claims tied to unexpected stability, dissolution, bioavailability or taste-masking results would be more defensible.

A sponsor could pursue U.S. and international applications covering the composition, process and use. The practical value would depend on the remaining patent term, regulatory exclusivity, jurisdictional malaria burden and the likelihood of generic substitution.

What is the Orange Book and FDA regulatory status of Arakoda?

Arakoda is an FDA-approved prescription drug under NDA 210607. Its approved dosage form is a 100 mg film-coated tablet. The FDA label identifies the approved indication, dose, contraindications, warnings and inactive ingredients. [1]

The key regulatory points are:

Regulatory issue	Arakoda position
FDA pathway	New drug application
Active ingredient	Tafenoquine, administered as tafenoquine succinate
Dosage form	Immediate-release film-coated tablet
Generic pathway	ANDA, subject to pharmaceutical equivalence and bioequivalence
Biosimilar pathway	Not applicable; tafenoquine is a small molecule
NCE exclusivity	Historical exclusivity period associated with initial approval has expired
Orphan exclusivity	Not the principal commercial protection for malaria prophylaxis
Orange Book relevance	Listed patents, if any, determine certain ANDA timing and Paragraph IV exposure

Tafenoquine was also approved as Krintafel for prevention of relapse of Plasmodium vivax malaria. Krintafel is a separate FDA product with a different indication and dosing regimen. The existence of Krintafel does not create a biosimilar issue because both products are small-molecule drugs. It can, however, affect active-moiety exclusivity and generic regulatory analysis. [3]

When does Arakoda lose exclusivity and what generic entry risks exist?

The principal FDA exclusivity periods associated with the original approvals have expired. Current commercial protection therefore depends on any unexpired listed patent, formulation patent, method-of-use patent or contractual supply arrangement.

A generic applicant could pursue an ANDA for a tafenoquine tablet if it can demonstrate pharmaceutical equivalence and bioequivalence. The applicant would need to address:

• Tafenoquine succinate strength and active-moiety equivalence.
• Dissolution similarity.
• Impurity and degradation controls.
• Tablet and coating specifications.
• Labeling and contraindication alignment.
• G6PD testing and risk-management language.

A Paragraph IV certification could challenge any unexpired Orange Book-listed patent. The most credible litigation targets would be later-issued patents covering a specific formulation, dosing regimen or manufacturing process. Generic applicants could also use Paragraph III certifications to wait for patent expiration where applicable. [4]

The generic risk is structurally higher for Arakoda than for products protected by a dense patent estate. The formulation is an immediate-release tablet using widely available excipient classes, and the product does not rely on a complex delivery system. A sponsor seeking to delay generic entry would need differentiated claims supported by strong comparative data.

How does Arakoda compare with Krintafel?

Arakoda and Krintafel contain the same active moiety but address different malaria-use cases.

Attribute	Arakoda	Krintafel
Active ingredient	Tafenoquine	Tafenoquine
Main indication	Malaria prophylaxis	Radical cure and relapse prevention of P. vivax malaria
Typical dosing concept	Loading dose followed by weekly dosing	Single-dose treatment with chloroquine
Commercial customers	Travelers, military, government and occupational users	Patients with P. vivax infection and healthcare systems
Adherence advantage	Weekly maintenance schedule	Single-dose administration
Main safety constraint	G6PD deficiency and psychiatric warnings	G6PD deficiency and related label restrictions
Lifecycle opportunity	200 mg tablet, dispersible product, field packaging	Combination or adherence-oriented products

Arakoda has broader potential in travel and deployment markets because malaria prophylaxis is used before and during exposure. Krintafel has a more targeted clinical market but benefits from single-dose administration.

The two products could compete for manufacturing capacity, clinical development resources and institutional procurement attention. They should not be treated as interchangeable products because their indications and dosing regimens differ.

Which companies are challenging Arakoda, and what is the litigation status?

No major biosimilar challenge applies to Arakoda. Any competitive challenge would come from a generic tafenoquine manufacturer or from an alternative antimalarial product.

The likely competitive pathways are:

1. An ANDA for a 100 mg tafenoquine tablet.
2. A 200 mg reformulated product with improved adherence.
3. A generic or authorized-generic supply agreement.
4. Competing malaria prophylaxis products such as atovaquone/proguanil, doxycycline and mefloquine.
5. Institutional procurement competition involving price, shelf life and logistics.

The commercial litigation risk is therefore more likely to arise from Paragraph IV patent litigation than from biosimilar litigation. A public, high-value litigation record would depend on a sponsor first obtaining and listing later formulation or method patents. The original approval alone does not create a continuing market barrier.

What licensing deals and commercial partnerships could support Arakoda?

Arakoda’s commercial opportunity is well suited to licensing and supply arrangements rather than a purely retail strategy. Relevant counterparties include:

• Defense procurement agencies.
• Government malaria-control programs.
• Travel-medicine distributors.
• Global-health organizations.
• Regional pharmaceutical manufacturers.
• Contract manufacturers with high-barrier blister and tablet-coating capacity.

Potential deal structures include territorial licenses, government framework contracts, co-development of a 200 mg tablet, authorized-generic rights and co-packaging arrangements with G6PD testing services.

The most commercially defensible asset would be a differentiated dosage form supported by regulatory exclusivity or formulation patents. A supply agreement for the existing 100 mg tablet could generate volume but would provide limited long-term differentiation unless supported by procurement preference, manufacturing scale or geographic rights.

How strong is the Arakoda patent estate?

Arakoda’s current patent strength is better characterized as moderate-to-weak for the existing conventional tablet and potentially stronger for new formulation technology.

Patent factor	Assessment
Active-molecule protection	Historical protection; not a current primary barrier
Existing tablet formulation	Conventional excipient platform; generic design-around risk is high
Method-of-use protection	Potentially relevant, but malaria prophylaxis dosing claims must be evaluated against prior art and FDA listing status
New 200 mg strength	Potentially patentable only with novel technical features
Pediatric or dispersible formulation	Higher lifecycle value if supported by pharmacokinetic and usability data
Manufacturing process	Potentially useful for trade-secret and patent protection
Geographic coverage	U.S. value is linked to FDA substitution; endemic-market value depends on local filings and procurement
Litigation exposure	Concentrated in any later-listed formulation or use patents

The best protection strategy would combine patents with regulatory filings, manufacturing know-how, high-barrier packaging and institutional contracts. Excipients alone rarely create durable exclusivity. Their value arises when they produce a measurable performance advantage that can be claimed and defended.

What are the main commercial opportunities for Arakoda excipients?

The highest-value opportunities are:

• A 200 mg tablet that reduces two-tablet dosing to one tablet.
• A taste-masked dispersible or orally disintegrating tablet.
• A pediatric or weight-based formulation for patients below the current adult-use threshold.
• A heat- and humidity-stable package for military and tropical deployment.
• Unit-dose blistering for travel and adherence.
• A co-pack containing tafenoquine and G6PD-testing support.
• Regional licensing for government malaria-prevention programs.
• A contract-manufacturing platform using standard excipients and high-throughput compression.

The preferred commercial sequence would be a 200 mg immediate-release tablet first, followed by a dispersible or pediatric product if clinical demand justifies development costs. A liquid product has a broader usability proposition but also carries greater stability, dosing and preservative complexity.

Key Takeaways

• Arakoda is a 100 mg tafenoquine succinate immediate-release tablet approved for adult malaria prophylaxis.
• The existing regimen requires two tablets per administration, creating a clear opportunity for a 200 mg tablet.
• Mannitol, copovidone, crospovidone, magnesium stearate and a film-coating system support a conventional, manufacturable tablet platform.
• The strongest formulation opportunities are higher-strength dosing, taste masking, pediatric delivery and tropical-climate stability.
• Tafenoquine is a small molecule, so biosimilar risk does not apply. Generic ANDA and Paragraph IV risk do apply.
• Original regulatory exclusivity has expired, making any current patent protection highly dependent on listed formulation, method-of-use or process patents.
• The commercial market includes travelers, military users, government stockpiles and malaria-control programs.
• A durable lifecycle strategy should combine formulation patents, regulatory filings, packaging technology, manufacturing know-how and institutional licensing.

FAQs

Can Arakoda be reformulated as a 300 mg tablet?

A 300 mg tablet could align with some tafenoquine dosing concepts, but it would not directly match the approved Arakoda prophylaxis regimen, which uses 200 mg loading, maintenance and terminal doses. A 300 mg format would require a separate clinical and regulatory rationale.

Would a tafenoquine orally disintegrating tablet require new clinical trials?

The extent of clinical data would depend on formulation changes and comparative bioavailability. A product with equivalent exposure may rely primarily on pharmaceutical and clinical pharmacology studies, while a materially different delivery system could require broader evidence.

Is mannitol a suitable excipient for pediatric tafenoquine?

Mannitol is commonly used in pediatric and orally disintegrating dosage forms, but its suitability would depend on dose, gastrointestinal tolerance, tablet size, taste-masking performance and the complete excipient profile.

Could Arakoda be supplied through government stockpiles?

Yes. Its long dosing interval and tablet stability profile are compatible with institutional procurement. Stockpile economics would depend on shelf life, packaging, procurement pricing, replenishment cycles and malaria-risk geography.

What is the most defensible Arakoda formulation patent strategy?

A patent focused on a measurable technical result, such as improved stability, taste masking, dissolution, bioavailability or dose uniformity, is more defensible than a broad claim covering tafenoquine with standard tablet excipients.

References

1. U.S. Food and Drug Administration. (2018). Arakoda (tafenoquine succinate) tablets, prescribing information. 60 Degrees Pharmaceuticals, LLC.

2. National Library of Medicine. (n.d.). DailyMed: Arakoda- tafenoquine succinate tablet, film coated. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (2018). Krintafel (tafenoquine) tablets, prescribing information. GlaxoSmithKline LLC.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.